3 ms·
The trial was on non-hospitalized patients, because you can't test impact on hospitalization risk with patients that are already hospitalized. But given the s
by loeg 5y ago
The trial was on non-hospitalized patients, because you can't test impact on hospitalization risk with patients that are already hospitalized. But given the supposed mechanism of action, I don't think there's any reason to believe it would not also be an effective therapy for hospitalized patients.
- matt_heimer 5y agoThis drug is an antiviral and isn't the Covid viral load already on the decline by the time that most people are hospitalized? See Fig 2 from https://www.bmj.com/content/371/bmj.m3862 https://www.bmj.com/content/371/bmj.m3862 . Its the other issues like the inflammatory cytokine response, tissue damage, and secondary infections that cause the poor outcomes in most hospitalized patients. So you'd need to take any antiviral early on. I think they said within 5 days in this study. Also of interest is that the 5 day marker is where the mild and severe cases diverge according to the article I linked to.
- linuxftw 5y agoIt makes one wonder why they administer remdesivir and other similar drugs to hospitalized patients.